跳转到内容

格列齐特：修订间差异

维基百科，自由的百科全书
以互动方式浏览历史
←上一版本
删除的内容 添加的内容
可视化wikitext
Skirtick（留言 | 贡献）
1,524次编辑
无编辑摘要
标签：移动版编辑 移动版网页编辑 高级移动版编辑
 
（未显示8个用户的11个中间版本）
第1行： 第1行：
{{medical}}
{{Drugbox
{{Drugbox
| verifiedrevid = 459476800
| verifiedrevid = 459476800
第44行： 第45行：
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N
| StdInChIKey = BOVGTQGAOIONJV-UHFFFAOYSA-N
}}
}}
'''格列齐特（{{lang-en|Gliclazide}}）'''，商品名为'''达美康'''。是一种[[磺酰脲类]]口服[[抗糖尿病药]]。 <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref><ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref>. 格列齐特可以防止因高血糖引起的细胞凋亡，保护人体的[[胰岛|胰岛β细胞]]。<ref>{{cite journal |pages=234–8 |doi=10.1002/dmrr.680 |title=Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |year=2007 |last1=Del Guerra |first1=S |last2=Grupillo |first2=M |last3=Masini |first3=M |last4=Lupi |first4=R |last5=Bugliani |first5=M |last6=Torri |first6=S |last7=Boggi |first7=U |last8=Del Chiaro |first8=M |last9=Vistoli |first9=F |last10=Mosca |first10=F |last11=Del Prato |first11=S |last12=Marchetti |first12=P |journal=Diabetes/Metabolism Research and Reviews |volume=23 |issue=3 |pmid=16952202|display-authors=8 }}</ref> 格列齐特还可以防止因[[2型糖尿病]]导致的[[动脉粥样硬化]]（防止动脉脂肪堆积）。<ref>{{cite journal |pages=1906–13 |doi=10.1007/s00125-004-1547-8 |title=Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes |year=2004 |last1=Katakami |first1=N. |last2=Yamasaki |first2=Y. |last3=Hayaishi-Okano |first3=R. |last4=Ohtoshi |first4=K. |last5=Kaneto |first5=H. |last6=Matsuhisa |first6=M. |last7=Kosugi |first7=K. |last8=Hori |first8=M. |journal=Diabetologia |volume=47 |issue=11 |pmid=15565373}}</ref>格列齐特在中国作为一线药物使用，应用十分广泛，而在其他国家却并不常用。
'''格列齐特'''（{{lang-en|Gliclazide}}），商品名为'''达美康'''。是一种[[磺酰脲类]]口服[[抗糖尿病药]]。 <ref name="pmid2106423">{{cite journal |pages=109–14 |doi=10.1016/0168-8227(90)90020-T |title=Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds |url=https://archive.org/details/sim_diabetes-research-and-clinical-practice_1990_8_2/page/109 |year=1990 |last1=Ballagi-Pordány |first1=György |last2=Köszeghy |first2=Anna |last3=Koltai |first3=Mária-Zsófia |last4=Aranyi |first4=Zoltán |last5=Pogátsa |first5=Gábor |journal=Diabetes Research and Clinical Practice |volume=8 |issue=2 |pmid=2106423}}</ref><ref>{{cite journal |pages=722–30 |doi=10.1016/j.metabol.2006.01.019 |title=Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation |year=2006 |last1=Shimoyama |first1=Tatsuhiro |last2=Yamaguchi |first2=Shinya |last3=Takahashi |first3=Kazuto |last4=Katsuta |first4=Hidenori |last5=Ito |first5=Eisuke |last6=Seki |first6=Hiroyuki |last7=Ushikawa |first7=Kenji |last8=Katahira |first8=Hiroshi |last9=Yoshimoto |first9=Katsuhiko |last10=Ohno |first10=Hideki |last11=Nagamatsu |first11=Shinya |last12=Ishida |first12=Hitoshi |journal=Metabolism |volume=55 |issue=6 |pmid=16713429|display-authors=8 }}</ref>. 格列齐特可以防止因高血糖引起的[[细胞凋亡]]，保护人体的[[胰岛|胰岛β细胞]]。<ref>{{cite journal |pages=234–8 |doi=10.1002/dmrr.680 |title=Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |year=2007 |last1=Del Guerra |first1=S |last2=Grupillo |first2=M |last3=Masini |first3=M |last4=Lupi |first4=R |last5=Bugliani |first5=M |last6=Torri |first6=S |last7=Boggi |first7=U |last8=Del Chiaro |first8=M |last9=Vistoli |first9=F |last10=Mosca |first10=F |last11=Del Prato |first11=S |last12=Marchetti |first12=P |journal=Diabetes/Metabolism Research and Reviews |volume=23 |issue=3 |pmid=16952202|display-authors=8 }}</ref> 格列齐特还可以防止因[[2型糖尿病]]导致的[[动脉粥样硬化]]（防止动脉脂肪堆积）。<ref>{{cite journal |pages=1906–13 |doi=10.1007/s00125-004-1547-8 |title=Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes |year=2004 |last1=Katakami |first1=N. |last2=Yamasaki |first2=Y. |last3=Hayaishi-Okano |first3=R. |last4=Ohtoshi |first4=K. |last5=Kaneto |first5=H. |last6=Matsuhisa |first6=M. |last7=Kosugi |first7=K. |last8=Hori |first8=M. |journal=Diabetologia |volume=47 |issue=11 |pmid=15565373}}</ref>格列齐特在中国作为一线药物使用，应用极为广泛，而在其他国家却并不常用。Diamicron ( Gliclazide)

==药理==
格列齐特为[[胰島素]]增泌剂，通过抑制[[胰岛|胰岛β细胞]]的{{le|ATP-sensitive potassium channel}}，从而促进胰岛素的释放。


==引用==
==引用==
{{reflist}}
{{reflist}}

{{-}}

{{口服降糖药和胰岛素类似物}}
{{Diabetes}}


[[Category:糖尿病药物]]
[[Category:糖尿病药物]]
[[Category:对甲苯磺酰基化合物]]

2024年6月23日 (日) 18:52的最新版本

维基百科中的醫學内容仅供参考，並不能視作專業意見。如需獲取醫療幫助或意見，请咨询专业人士。詳見醫學聲明。
格列齐特
臨床資料
商品名（英语：Drug nomenclature）达美康
AHFS/Drugs.comMicromedex详细消费者药物信息
懷孕分級
  • 澳: C
给药途径口服
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物半衰期10.4小时
识别信息
  • N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide
CAS号21187-98-4  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)
ECHA InfoCard100.040.221 編輯維基數據鏈接
化学信息
化学式C15H21N3O3S
摩尔质量323.412 g/mol
3D模型（JSmol（英语：JSmol））
  • O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
  • InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) checkY
  • Key:BOVGTQGAOIONJV-UHFFFAOYSA-N checkY

格列齐特（英語：Gliclazide），商品名为达美康。是一种磺酰脲类口服抗糖尿病药。 [1][2]. 格列齐特可以防止因高血糖引起的细胞凋亡，保护人体的胰岛β细胞。[3] 格列齐特还可以防止因2型糖尿病导致的动脉粥样硬化（防止动脉脂肪堆积）。[4]格列齐特在中国作为一线药物使用，应用极为广泛，而在其他国家却并不常用。Diamicron ( Gliclazide)

药理

[编辑]

格列齐特为胰島素增泌剂，通过抑制胰岛β细胞的ATP-sensitive potassium channel（英语：ATP-sensitive potassium channel），从而促进胰岛素的释放。

引用

[编辑]
  1. ^ Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Research and Clinical Practice. 1990, 8 (2): 109–14. PMID 2106423. doi:10.1016/0168-8227(90)90020-T. 
  2. ^ Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; et al. Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism. 2006, 55 (6): 722–30. PMID 16713429. doi:10.1016/j.metabol.2006.01.019. 
  3. ^ Del Guerra, S; Grupillo, M; Masini, M; Lupi, R; Bugliani, M; Torri, S; Boggi, U; Del Chiaro, M; et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes/Metabolism Research and Reviews. 2007, 23 (3): 234–8. PMID 16952202. doi:10.1002/dmrr.680. 
  4. ^ Katakami, N.; Yamasaki, Y.; Hayaishi-Okano, R.; Ohtoshi, K.; Kaneto, H.; Matsuhisa, M.; Kosugi, K.; Hori, M. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004, 47 (11): 1906–13. PMID 15565373. doi:10.1007/s00125-004-1547-8. 
检索自“https://zh.wikipedia.org/zhwiki/w/index.php?title=格列齐特&oldid=83146107”